Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | ADH5 | P11766 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990221 | 0.81 | CYP3A4 (0.55) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL4757507 | 0.81 | CYP3A4 (0.55) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL27834151 | 0.79 | CYP3A4 (0.53) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL7462893 | 0.78 | CYP3A4 (0.64) | CYP3A4BAZ2BHTTENPP2MKNK1 | |
| SCHEMBL27814146 | 0.78 | CYP3A4 (0.55) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL8781221 | 0.77 | CYP3A4 (0.54) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| Acrylic Acid SCHEMBL28324903 | 0.76 | CYP3A4 (0.70) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL10363643 | 0.76 | CYP3A4 (0.53) | CYP3A4BAZ2BHTTENPP2MKNK1 | |
| SCHEMBL27886414 | 0.75 | IDO1 (0.49) | CYP3A4BAZ2BCYP11B1CYP11B2HTT | |
| SCHEMBL445884 | 0.75 | CYP3A4 (0.58) | CYP3A4BAZ2BCYP11B1CYP11B2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| US-8183206-B2 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1437137-B1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | PLAT, PTGIS, SERPINC1 | CYP3A4 1183/4885BAZ2B 1567/4885CYP11B1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.